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Introduction
Colorectal cancer (CRC) is the third most prevalent cancer in men and the second in women throughout the world, with over 1.2 million new cancer cases and 608,700 cancer-related deaths in 2008 [1] . In the United States, the estimated new CRC cases and the estimated deaths in 2012 are 143,460 and 51,690, respectively [2] . While tumor stage remains the most important prognostic factor [3, 4] , considerable stage-independent variability exists in clinical outcome which underscores the need for the identification and validation of new predictive and prognostic biomarkers to guide therapeutic decisionmaking for personalized therapy. At present, the only marker that is routinely utilized in clinical practice is the tumor mutation status of the KRAS gene which predicts nonresponse to anti-EGFR antibodies, including cetuximab, in metastatic CRC patients [5] .
MicroRNAs (miRNAs) are endogenous 21-to 22-nucleotide non-coding RNAs [6, 7] that target messenger RNAs (mRNAs) and regulate their expression through complementarity to the 3'-UTRs of mRNAs [8, 9] . MiRNAs have been shown to play a role in cancer development and progression [10] [11] [12] [13] . The lethal-7 (let-7) family is widely viewed as tumor suppressor miRNA and the expression of let-7 family members is downregulated in cancers of the lung [12] , colorectum [14] and breast [15] . The human KRAS oncogene has been shown to contain multiple let-7 complementary sites (LCSs) in its 3'UTR [16] which subjects KRAS to let-7 miRNA-mediated regulation in vitro [14] and in vivo [17] . association studies have shown potential prognostic value of the LCS6 variant in early stage CRC [19] and in metastatic CRC patients with wild-type (WT) KRAS tumors receiving cetuximab [20] . However, its' clinical significance and association with KRAS mutation status remains controversial due to conflicting results in studies with limited sample sizes [21] [22] [23] .
Given this prior evidence, we hypothesized that the LCS6 variant is associated with KRAS mutation status and may be associated with poor prognosis in colon cancers.
We secondarily hypothesized that the LCS6 variant is inversely associated with BRAF V600E mutation and deficient DNA mismatch repair (dMMR). To test our hypothesis and further elucidate the significance of the LCS6 variant in a larger patient population, we genotyped the LCS6 variant in a large cohort of stage III colon cancer patients treated in a randomized trial of FOLFOX alone or combined with cetuximab as postoperative adjuvant chemotherapy (NCCTG N0147). In this study, the addition of cetuximab failed to increase disease-free survival (DFS) compared to FOLFOX alone [24] .
Materials and Methods

Study population
Patients were obtained from the NCCTG N0147 Trial, a large randomized phase III study in adjuvant colon cancer designed to assess the potential benefit of cetuximab in resected stage III colon cancer. Patients were enrolled in one of the following treatment arms: FOLFOX +/-cetuximab, FOLFIRI +/-cetuximab, 6 cycles of FOLFOX followed by 6 cycles of FOLFIRI ± cetuximab, and treatment per local physician discretion. A total of 3397 patients, of which 2686 patients with KRAS WT were concurrently G>A G13D) and BRAF (c.1799 T>A V600E) mutations and DNA mismatch repair proteins (dMMR vs. pMMR) were also available [24, 25] .
KRAS LCS6 genotyping
A total of 2834 Stage III colon cancer patients with available DNA from whole blood (N=2834) and paired formalin-fixed paraffin-embedded (FFPE) tumor specimens (N=977) were utilized for LCS6 genotyping. A previously published probe-based assay (Life Technologies, Grand Island, NY) was used to determine LCS6 variant status [26] 
Statistical Analysis
All statistical analysis of the LCS6 variant utilized genotype data obtained from whole blood. The primary objective was to assess the prognostic value of LCS6 status in terms of disease-free-survival (DFS) and time to recurrence (TTR). DFS was defined as the time from the date of randomization to the first documented disease recurrence or death from any causes. TTR was defined as time from the date of randomization to the first documented disease recurrence. For patients who died without recurrence, TTR was censored at the last disease evaluation date. Both DFS and TTR were censored at 4 years or last follow-up whichever was earlier. Chi-squared and unequal variance two-sample ttests were used to compare categorical and continuous baseline factors, respectively, between patients carrying the LCS6 variant (GG or GT) and patients with LCS6 wildtype (TT) [27, 28] . Logistic regression was used to assess the association between LCS6 status and clinical outcomes [28] . The method of Kaplan-Meier was used to estimate the distributions of DFS and TTR [29] . Cox model was used to assess the univariate and multivariate associations between LCS6 and clinical outcomes [30] . Unless otherwise specified, all multivariate models were adjusted for age, sex, race, performance score, with discrepant results identified in samples from two patients (sample 1: TT/blood and GT/tumor; sample 2: GT/blood and GG/tumor). Repeating the LCS6 genotyping assay for both whole blood and tumor-derived DNA from the two discrepant samples showed identical results.
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Association of the LCS6 variant with KRAS, BRAF and MMR status
The overall frequencies of KRAS mutant, BRAF mutant and dMMR tumors were 36.1%, 12.6% and 11.3%, respectively. No statistically significant differences were found between LCS6 variant and wild-type carriers for KRAS, BRAF or MMR status (all P>0.1, Table 2 ).
Prognostic impact of the LCS6 genotype
The 3-year DFS rate was 74.1% (number of events = 104; 95% CI = 69.5%-78.7%) and 72.5% (number of events = 606; 95% CI = 70.5-74.5%) in LCS6 variant and wildtype carriers, respectively (log-rank test, P=0.49, Figure 1A) . The 3 year recurrence-free survival rate was 75.7% (number of events = 93; 95% CI = 71.2%-80.3%) and 74.5%
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(number of events = 549; 95% CI = 72.6%-76.5%) in LCS6 variant and wild-type carriers, respectively (log-rank test, P =0.43, Figure 1B) . Within LCS6 variant and wildtype carriers, no statistically significant differences were found in DFS (HR 0.93, 95% CI: 0.76 to 1.14, Figure 1A ) or TTR (HR 0.92, 95% CI: 0.74 to 1.14, Figure 1B Figure 2C ), no statistically significant differences in DFS were found (Table 3 ). In addition, the LCS6 variant showed no significant interaction effect with KRAS mutation status (p=0.42), BRAF mutation status (p=0.16), MMR status (p=0.84), or tumor site (p=0.6616).
Discussion
Previous studies have established let-7 as a tumor suppressor miRNA which negatively regulates the RAS pathway [14, 16, 17] . smokers [18] . Since then, the LCS6 polymorphism has been studied extensively in other cancer types, such as oral cavity, ovarian, colorectal and breast [21, 26, [31] [32] . However, the clinical significance of the LCS6 polymorphism in different cancer types and among different stages within CRC has been inconsistent. In order to evaluate the significance of LCS6 variant in colon cancers, we focused on stage III cancer patients from a large, prospectively randomized clinical trial of adjuvant chemotherapy. Our association study indicates that the germline LCS6 genotype was not associated with KRAS mutation status or with clinical outcome in patients with stage III colon cancers.
Our study confirms that the LCS6 variant is a germline polymorphism with genotypes that were highly concordant (99.8%) in paired blood and tumor DNA. Similar to our findings, Sebio et al found a concordance rate of 98%, with two blood DNA samples displaying the LCS6 genotype TG, whereas the two paired tumor DNA samples showed the LCS6 genotype TT [23] . Though a rare occurrence, blood versus tumor DNA discrepancies could result from various events such as loss of heterozygosity in tumor samples, cross-contamination in tissue sampling, DNA fragmentation during the formalin fixation and paraffin embedding processing, or artifactual nucleotide substitutions from problematic PCR amplification [33, 34] .
Our study identified a significantly higher frequency of the LCS6 G-allele carriers in Caucasians compared to other races which is consistent with the published frequencies Caucasians MAF = 0.086; African MAF = 0.004) [35] . Importantly, racial differences in CRC incidence and mortality exist among Caucasian and African American populations [36] with African Americans being more likely to be diagnosed at a younger age, with late stage disease, proximal tumors, and worse prognosis compared with Caucasians [37] . To date, however, the biological and genetic basis for the existence of a more aggressive CRC phenotype in African Americans awaits further study.
Our analysis showed no associations between the LCS6 variant and either tumor localization, specific tumor subsites, or KRAS somatic mutation status. Tumor location has been shown to display distinct differences in molecular characteristics. Previous studies indicated KRAS-mutated carcinomas were more frequently located in the proximal compared with distal CRC [38] . In addition, cecal cancers have also exhibited the highest frequency of KRAS mutations [39] . In agreement with our findings, previous reports have also shown no correlation between the LCS6 variant and KRAS mutation status in both colon cancer [19] and non-small cell lung cancer [40] . These results suggest that LCS6 and KRAS somatic mutation status are independent events. A possible explanation is that KRAS upregulation accompanying the LCS6 variant does not result in any selective pressure for or against KRAS mutation [40] . However, Graziano et al.
reported a conflicting result showing a significantly greater frequency of LCS6 G-allele carriers in the KRAS mutation group compared to the KRAS wild-type group in metastatic CRC patients [21] . It is hypothesized that some clonal selection in tumors may occur, favoring less differentiated and more aggressive clones that harbor both activating KRAS mutations and LCS6. Though the role of LCS6 variant in KRAS mutation remains to be delineated, reported association discrepancies may be explained by the heterogeneity in tumor pathological type and stage, study design, or sample size.
In the current study, we failed to detect any significant association between the LCS6 polymorphism and survival in stage III colon cancer patients, even after combining LCS6 genotype with mutation status of either KRAS or BRAF, or with MMR status.
Conflicting data exist regarding this polymorphism in other stages of CRC. In this regard, a significantly better survival was reported in LCS6 G-allele carriers that was enhanced when combined with KRAS mutant status in early stage (stage I and II, n=409), but not in later stage (stage III, n=182 and stage IV, n=69) CRCs [19] . However, Ryan et al. recently showed associations between the LCS6 G allele and reduced risk of mortality in late stage (stage III and IV, n=124), but not in early stage (stage I and II, n=113) CRC patients [22] . Controversy also exists regarding the role of LCS6 polymorphism in prognosis of other solid tumors. A reduced survival was reported in oral cancer patients [26] , yet no association between the LCS6 polymorphism and survival was found in NSCLC [40] or ovarian cancer [32] . The conflicting evidence regarding the prognostic value of the LCS6 variant may be attributed to multiple factors: differences in study design, inadequate statistical power, selection bias, and heterogeneity within cancer stages and cancer types.
Our analysis also identified no interaction effect for the LCS6 variant and treatment arm (FOLFOX alone versus FOLFOX and cetuximab) and showed no associations between LCS6 variant status and DFS within the separate treatment groups.
Conflicting evidence also exists for the LCS6 variant as a predictive biomarker in KRAS wild-type CRC patients treated with cetuximab. In patients treated with salvage cetuximab-irinotecan therapy, significant associations were found between carriers of the LCS6 G-allele and adverse PFS and overall survival (OS) [21] . However, conflicting results were reported in metastatic CRC patients treated with cetuximab monotherapy with LCS6 wild-type (TT) patients showing a significantly decreased tumor response, but no association between LCS6 genotype and PFS or OS regardless of KRAS status [20] . Most recently, Sebio, et al. identified a significant decrease in tumor response rate in LCS6 G-allele carriers with refractory mCRC; however, there was no significant association between the LCS6 variant and PFS or OS [23] . This association was identified only in patients treated with anti-EGFR-based therapy either alone or in combination, not in patients treated with FOLFIRI alone. While the aforementioned studies were conducted in patients with treatment refractory disease, the Nordic trial was conducted in previously untreated patients with metastatic CRC. In this study, there was no statistically significant effect of the LCS6 variant allele on response rate, PFS or OS in patients treated with FLOX +/-cetuximab [41] .
Strengths of our study include the large number of paired blood and tumor specimens that were prospectively collected, analyzed at a single institution and from a clinical trial with meticulous data collection including recurrence and survival. We examined a uniform population of stage III colon cancers as compared to studies that include a mixture of stages with small sample sizes. To our knowledge, our study is the largest conducted to date that examines the LCS6 polymorphism in CRC patients with sufficient statistical power to detect the association between LCS6 variant, KRAS mutation status and disease outcome. However, our study has some limitations. Our trial cohort represents a highly selected group of stage III colon cancer patients through strict inclusion criteria. Thus, bias is unavoidable and geralizability of our findings needs to be proved in colon cancer with other stages (stage I, II and IV) and other cancer types. In addition, KRAS mutation profiling in the N0147 study population remains incomplete. colorectal cancer [42] . Furthermore, our adjuvant clinical trial population of stage III colon cancer patients is also unable to assess the potential association of the LCS6 variant with tumor response, although recurrence and survival were studied.
In conclusion, we report the largest association study investigating the LCS6 polymorphism and colon cancer outcome. We found that the LCS6 polymorphism is not associated with KRAS mutation status or with disease outcome in stage III colon cancer patients. However, the clinical utility of the LCS6 polymorphism in other stages of colon cancer is poorly understood and awaits further study. 
